SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-14 |
| Reported value | $470,359,288 |
| Positions | 29 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $81,915,580 | 1,431,590 |
| GILEAD SCIENCES INC | GILD | COM | $43,340,053 | 343,043 |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | COM | $28,571,960 | 1,089,701 |
| MADRIGAL PHARMACEUTICALS INC | MDGL | COM | $28,214,038 | 52,545 |
| BICARA THERAPEUTICS INC | BCAX | COM | $26,501,917 | 892,621 |
| RELMADA THERAPEUTICS INC | RLMD | COM | $25,293,119 | 3,655,075 |
| TREVI THERAPEUTICS INC | TRVI | COM | $24,976,304 | 1,339,212 |
| PHARVARIS N V | PHVS | COM | $23,441,056 | 677,879 |
| XENON PHARMACEUTICALS INC | XENE | COM | $22,206,444 | 367,900 |
| ANI PHARMACEUTICALS INC | ANIP | COM | $19,354,626 | 233,808 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.